<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839578</url>
  </required_header>
  <id_info>
    <org_study_id>2012.724</org_study_id>
    <nct_id>NCT01839578</nct_id>
  </id_info>
  <brief_title>Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances</brief_title>
  <acronym>RCA-SHA</acronym>
  <official_title>Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is responsible for 50% of all acute kidney injury (AKI) in intensive care units&#xD;
      (ICUs), contributing greatly to multiple organ dysfunction syndrome (MODS). Special types of&#xD;
      continuous renal replacement therapies (CRRT) have been proposed as adjuvant therapies for&#xD;
      septic shock due to their ability to remove middle molecular weight molecules such as&#xD;
      inflammatory mediators involved in MODS pathophysiology. These therapies are called&#xD;
      extracorporeal &quot; blood purification &quot; therapies.&#xD;
&#xD;
      When CRRT is used, an anticoagulation is required to prevent clotting of the extracorporeal&#xD;
      circuit, possibly causing bleeding in selected patients. Many anticoagulation strategies have&#xD;
      been proposed and the most commonly used in 2013 is still unfractionated heparin. Regional&#xD;
      citrate anticoagulation (RCA) is an interesting alternative as it dramatically decreases the&#xD;
      bleeding risk.&#xD;
&#xD;
      The investigators hypothesize that the use of citrate with Super High Flux Continuous&#xD;
      Veno-Venus Hemodialysis (SHF-CVVHD) would be highly beneficial over time by preserving the&#xD;
      filter effectiveness via limiting protein adhesion (which subsequently reduces filter pore&#xD;
      sizes (protein cake)), as compared to heparin. Consequently, higher clearances of the&#xD;
      inflammatory mediators could be maintained over time with citrate as compared to heparin&#xD;
      anticoagulation. In other words, for the same duration of filter use, middle molecular weight&#xD;
      molecules and cytokines clearances would be greater with citrate as compared to heparin. To&#xD;
      test this hypothesis, the investigators will perform a clinical randomized controlled trial&#xD;
      which aim would be to compare middle molecular weight molecules and cytokines clearances in&#xD;
      SHF-CVVHD using RCA versus systemic heparin anticoagulation in septic patients with AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Middle molecular weight molecules clearances</measure>
    <time_frame>18 months</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), blood and post-filter samplings will be taken in order to calculate kappa and lambda light chains of immunoglobulin clearances.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearances of cytokines and molecules of interest</measure>
    <time_frame>T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), sampling will be simultaneously collected from blood and post-filter in order to determine cytokines (IL-1 ra, IL-10, IL-6, IL-8, β2microglobuline), urea, creatinine and albumin clearances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), clinical data and blood sampling will be collected in order to assess mean arterial pressure, heart rate, vasopressor requirement and lactate level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters</measure>
    <time_frame>(T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h),</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), PaO2/FIO2 ratio will be measured by blood sampling and clinical data collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28th day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>RCA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHF-CVVHD with regional citrate anticoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHF-CVVHD with systemic heparin anticoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)</intervention_name>
    <description>Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.&#xD;
Ci-Ca protocole for MultiFiltrate® CRRT machine :&#xD;
4% trisodium citrate solution&#xD;
Calcium chloride solution (100 mmol/L)&#xD;
Dialysate flow rate: 35 ml/kg/h&#xD;
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3&#xD;
Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.&#xD;
Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.&#xD;
Blood flow adapted to the acid-base status</description>
    <arm_group_label>RCA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)</intervention_name>
    <description>Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.&#xD;
Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.&#xD;
Standard dialysate for CRRT : Prismasol® K2 solution&#xD;
Dialysate flow rate: 35 ml/kg/h&#xD;
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of</description>
    <arm_group_label>Heparin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female critically ill patients over the age of 18 years old&#xD;
&#xD;
          -  Acute Kidney Injury requiring CRRT defined using the Risk, Injury, Failure, Loss,&#xD;
             End-stage renal disease (RIFLE) classification with criterion I or worse.&#xD;
&#xD;
          -  Septic shock as defined by the American College of Chest Physicians/Society of&#xD;
             Critical Care Medicine Consensus Conference.&#xD;
&#xD;
          -  Written informed consent obtained from the patient or a patient's legal representative&#xD;
&#xD;
          -  Patient patient's legal representative able to agree to patient's enrollment in the&#xD;
             study with informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Participation in another research study protocol&#xD;
&#xD;
          -  Known heparin induced thrombopenia or contraindication to heparin&#xD;
&#xD;
          -  Pre-existing chronic renal failure on chronic dialysis&#xD;
&#xD;
          -  Therapeutic anticoagulation with heparin for another reason (e.g. chonic arrhythmia)&#xD;
&#xD;
          -  Severe liver failure (15% prothrombin time)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Rimmelé, Dr</last_name>
    <phone>4 72 11 02 13</phone>
    <phone_ext>+33</phone_ext>
    <email>th.rimmele@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pr Bernard Allaouchiche, Pr</last_name>
    <phone>4 72 11 02 13</phone>
    <phone_ext>+33</phone_ext>
    <email>bernard.allaouchiche@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Réanimation - Pavillon P, Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Rimmelé, Dr</last_name>
      <phone>4 72 11 02 13</phone>
      <phone_ext>+33</phone_ext>
      <email>th.rimmele@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bernard Allaouchiche, Pr</last_name>
      <phone>4 72 11 02 13</phone>
      <phone_ext>+33</phone_ext>
      <email>bernard.allaouchiche@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Rimmelé, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Allaouchiche, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles-Eric Ber, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jullien Crozon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Page, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanne Prothet, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Jacques Baillon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise Christin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Floccard, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Guillaume, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Martin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Marcotte, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Hautin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Faure, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Geffriaud, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Malavieille, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytokines</keyword>
  <keyword>blood purification</keyword>
  <keyword>super high flux hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

